Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur

BMC Microbiology

Volumn 11, Issue , 2011, Pages

  Berrêdo Pinho, Marcia ^a   Kalume, Dario E ^a   Correa, Paloma R ^a   Gomes, Leonardo H F ^a   Pereira, Melissa P ^a   Da Silva, Renata F ^a   Castello Branco, Luiz R R ^b   Degrave, Wim M ^a   Mendonça Lima, Leila ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Fundacao Ataulpho de Paiva   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; CULTURE FILTRATE PROTEIN; UNCLASSIFIED DRUG; PROTEOME;

ARTICLE; BACTERIAL STRAIN; IMMUNOGENICITY; MASS SPECTROMETRY; MYCOBACTERIUM BOVIS; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; BRAZIL; CHEMISTRY; CULTURE MEDIUM; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

MYCOBACTERIUM BOVIS BCG;

BACTERIAL PROTEINS; BCG VACCINE; BRAZIL; CULTURE MEDIA; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; MYCOBACTERIUM BOVIS; PROTEOME;

EID: 79954569547     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-11-80     Document Type: Article

References (86)

1. Global Tuberculosis Control, Surveillance, Planning, Financing. WHO, Geneva: World Health Organization 2008
2. Global epidemiology of tuberculosis. C Dye, Lancet 2006 367 938 940 10.1016/S0140-6736(06)68384-0 16546542
3. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. MA Aziz A Wright A Laszlo A De Muynck F Portaels A Van Deun C Wells P Nunn L Blanc M Raviglione, Lancet 2006 368 2142 2154 10.1016/S0140-6736(06)69863-2 17174706 (Pubitemid 44914009)
4. Mapping the global use of different BCG vaccine strains. N Ritz N Curtis, Tuberculosis (Edinb) 2009 89 248 251 10.1016/j.tube.2009.03.002
5. Sur la vaccination preventive des enfants nouveau-nés contre la tuberculose par le BCG. A Calmette C Guerin L Negre A Bocquet, Ann Inst Pasteur (Paris) 1927 3 201 208
6. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. GG Mahairas PJ Sabo MJ Hickey DC Singh CK Stover, J Bacteriol 1996 178 1274 1282 8631702 (Pubitemid 26073382)
7. Comparative genomics of BCG vaccines by whole-genome DNA microarray. MA Behr MA Wilson WP Gill H Salamon GK Schoolnik S Rane PM Small, Science 1999 284 1520 1523 10.1126/science.284.5419.1520 10348738
8. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. SV Gordon R Brosch A Billault T Garnier K Eiglmeier ST Cole, Mol Microbiol 1999 32 643 655 10.1046/j.1365-2958. 1999.01383.x 10320585 (Pubitemid 29233907)
9. The evolution of mycobacterial pathogenicity: clues from comparative genomics. R Brosch AS Pym SV Gordon ST Cole, Trends Microbiol 2001 9 452 458 10.1016/S0966-842X(01)02131-X 11553458 (Pubitemid 32844332)
10. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review. TC Benevolo-de-Andrade R Monteiro-Maia C Cosgrove LR Castello-Branco, Mem Inst Oswaldo Cruz 2005 100 459 465 10.1590/S0074-02762005000500002 16184220 (Pubitemid 41430288)
11. Genome plasticity of BCG and impact on vaccine efficacy. R Brosch SV Gordon T Garnier K Eiglmeier W Frigui P Valenti S Dos Santos S Duthoy C Lacroix C Garcia-Pelayo JK Inwald P Golby JN Garcia RG Hewinson MA Behr MA Quail C Churcher BG Barrell J Parkhill ST Cole, Proc Natl Acad Sci USA 2007 104 5596 5601 10.1073/pnas.0700869104 17372194 (Pubitemid 47175726)
12. Long lasting BCG protection against leprosy. LC Rodrigues LR Kerr-Pontes MV Frietas ML Barreto, Vaccine 2007 25 6842 6844 10.1016/j.vaccine.2007.07.032 17728023 (Pubitemid 47391109)
13. The success and failure of BCG - implications for a novel tuberculosis vaccine. P Andersen TM Doherty, Nat Rev Microbiol 2005 3 656 662 10.1038/nrmicro1211 16012514 (Pubitemid 41052152)
14. New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. PR Antas LR Castello-Branco, Trans R Soc Trop Med Hyg 2008 102 628 630 10.1016/j.trstmh.2008.03.014 18440575
15. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. AI Castillo-Rodal M Castanon-Arreola R Hernandez-Pando JJ Calva E Sada-Diaz Y Lopez-Vidal, Infect Immun 2006 74 1718 1724 10.1128/IAI.74.3.1718-1724.2006 16495544 (Pubitemid 43346806)
16. Phenotypic differences between BCG vaccines at the proteome level. M Rodriguez-Alvarez G Mendoza-Hernandez S Encarnacion JJ Calva Y Lopez-Vidal, Tuberculosis (Edinb) 2009 89 126 135 10.1016/j.tube.2008.12.001
17. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. L Brandt J Feino Cunha A Weinreich Olsen B Chilima P Hirsch R Appelberg P Andersen, Infect Immun 2002 70 672 678 10.1128/IAI.70.2.672-678.2002 11796598 (Pubitemid 34083827)
18. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. GA Colditz TF Brewer CS Berkey ME Wilson E Burdick HV Fineberg F Mosteller, JAMA 1994 271 698 702 10.1001/jama.271.9.698 8309034 (Pubitemid 24061706)
19. Issues Relating to the Use of BCG in Immunisation Programmes. A discussion document. PE Fine IA Carneiro JB Milstien CJ Clements, Geneva: World Health Organisation. Department of Vaccines and Biologicals 1999 1 45 1-45
20. Immunomodulatory action of mycobacterial secretory proteins. V Trajkovic K Natarajan P Sharma, Microbes Infect 2004 6 513 519 10.1016/j.micinf.2003.12. 015 15109967 (Pubitemid 38510608)
21. Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. H Malen FS Berven KE Fladmark HG Wiker, Proteomics 2007 7 1702 1718 10.1002/pmic.200600853 17443846 (Pubitemid 46841830)
22. Immunization of mice with mycobacterial culture filtrate proteins. RD Hubbard CM Flory FM Collins, Clin Exp Immunol 1992 87 94 98 1733641
23. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. P Andersen, Infect Immun 1994 62 2536 2544 7910595 (Pubitemid 24157087)
24. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. MA Horwitz G Harth BJ Dillon S Maslesa-Galic, Proc Natl Acad Sci USA 2000 97 13853 13858 10.1073/pnas.250480397 11095745
25. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. AT Kamath AF Rochat MP Valenti EM Agger K Lingnau P Andersen PH Lambert CA Siegrist, PLoS One 2008 3 3683 10.1371/journal.pone.0003683 18997860
26. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. E Badell F Nicolle S Clark L Majlessi F Boudou A Martino L Castello-Branco C Leclerc DJ Lewis PD Marsh B Gicquel N Winter, Vaccine 2009 27 28 37 10.1016/j.vaccine.2008.10.034 18977269
27. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. H Boesen BN Jensen T Wilcke P Andersen, Infect Immun 1995 63 1491 1497 7890415
28. Antigen analysis of Mycobacterium tuberculosis H37Rv culture filtrate proteins. H Målen T Softeland HG Wiker, Scand J Immunol 2008 67 245 252 10.1111/j.1365-3083.2007.02064.x 18208443 (Pubitemid 351197165)
29. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. J Liu V Tran AS Leung DC Alexander B Zhu, Hum Vaccin 2009 5 70 78 10.4161/hv.5.2.7210 19164935
30. Improved prediction of signal peptides: SignalP 3.0. JD Bendtsen H Nielsen G von Heijne S Brunak, J Mol Biol 2004 340 783 795 10.1016/j.jmb.2004. 05.028 15223320 (Pubitemid 38829638)
31. Prediction of lipoprotein signal peptides in Gram-negative bacteria. AS Juncker H Willenbrock G Von Heijne S Brunak H Nielsen A Krogh, Protein Sci 2003 12 1652 1662 10.1110/ps.0303703 12876315 (Pubitemid 36910046)
32. Prediction of twin-arginine signal peptides. JD Bendtsen H Nielsen D Widdick T Palmer S Brunak, BMC Bioinformatics 2005 6 167 10.1186/1471-2105-6-167 15992409
33. Non-classical protein secretion in bacteria. JD Bendtsen L Kiemer A Fausboll S Brunak, BMC Microbiol 2005 5 58 10.1186/1471-2180-5-58 16212653
34. High accuracy mass spectrometry analysis as a tool to verify and improve gene annotation using Mycobacterium tuberculosis as an example. GA de Souza H Malen T Softeland G Saelensminde S Prasad I Jonassen HG Wiker, BMC Genomics 2008 9 316 10.1186/1471-2164-9-316 18597682
35. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. A Krogh B Larsson G von Heijne EL Sonnhammer, J Mol Biol 2001 305 567 580 10.1006/jmbi.2000.4315 11152613 (Pubitemid 33032862)
36. Proteomics-based consensus prediction of protein retention in a bacterial membrane. H Tjalsma JM van Dijl, Proteomics 2005 5 4472 4482 10.1002/pmic.200402080 16220534 (Pubitemid 41739924)
37. Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. C Horn A Namane P Pescher M Riviere F Romain G Puzo O Barzu G Marchal, J Biol Chem 1999 274 32023 32030 10.1074/jbc.274.45.32023 10542234
38. Translation elongation factor EF-Tu is a target for Stp, a serine-threonine phosphatase involved in virulence of Listeria monocytogenes. C Archambaud E Gouin J Pizarro-Cerda P Cossart O Dussurget, Mol Microbiol 2005 56 383 396 10.1111/j.1365-2958.2005.04551.x 15813732 (Pubitemid 40516779)
39. The Mycobacterium tuberculosis cell-surface glycoprotein apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. A Ragas L Roussel G Puzo M Riviere, J Biol Chem 2007 282 5133 5142 17158455 (Pubitemid 47093750)
40. The FHA-containing protein GarA acts as a phosphorylation-dependent molecular switch in mycobacterial signaling. P England A Wehenkel S Martins S Hoos G Andre-Leroux A Villarino PM Alzari, FEBS Lett 2009 583 301 307 10.1016/j.febslet.2008.12.036 19114043
41. Asparagine deamidation: a regulatory hourglass. SJ Weintraub SR Manson, Mech Ageing Dev 2004 125 255 257 10.1016/j.mad.2004.03.002 15063100 (Pubitemid 38438503)
42. Whole proteome analysis of post-translational modifications: applications of mass-spectrometry for proteogenomic annotation. N Gupta S Tanner N Jaitly JN Adkins M Lipton R Edwards M Romine A Osterman V Bafna RD Smith PA Pevzner, Genome Res 2007 17 1362 1377 10.1101/gr.6427907 17690205 (Pubitemid 47360911)
43. Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions. A Villarino R Duran A Wehenkel P Fernandez P England P Brodin ST Cole U Zimny-Arndt PR Jungblut C Cervenansky PM Alzari, J Mol Biol 2005 350 953 963 10.1016/j.jmb.2005.05.049 15978616 (Pubitemid 40943454)
44. N-formylmethionyl peptides as chemoattractants for leucocytes. E Schiffmann BA Corcoran SM Wahl, Proc Natl Acad Sci USA 1975 72 1059 1062 10.1073/pnas.72.3.1059 1093163
45. The diversity of acetylated proteins. B Polevoda F Sherman, Genome Biol 2002 3 eviews0006 12049668
46. CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. LM Okkels EC Muller M Schmid I Rosenkrands SH Kaufmann P Andersen PR Jungblut, Proteomics 2004 4 2954 2960 10.1002/pmic.200400906 15378760 (Pubitemid 39372378)
47. Type VII secretion - mycobacteria show the way. AM Abdallah NC Gey van Pittius PA Champion J Cox J Luirink CM Vandenbroucke-Grauls BJ Appelmelk W Bitter, Nat Rev Microbiol 2007 5 883 891 10.1038/nrmicro1773 17922044 (Pubitemid 47578389)
48. Characterization of the twin-arginine translocase secretion system of Mycobacterium smegmatis. JE Posey TM Shinnick FD Quinn, J Bacteriol 2006 188 1332 1340 10.1128/JB.188.4.1332-1340.2006 16452415 (Pubitemid 43228666)
49. Systematic genetic nomenclature for type VII secretion systems. W Bitter EN Houben D Bottai P Brodin EJ Brown JS Cox K Derbyshire SM Fortune LY Gao J Liu J Liu NC Gey van Pittius AS Pym EJ Rubin DR Sherman ST Cole R Brosch, PLoS Pathog 2009 5 1000507 10.1371/journal.ppat.1000507 19876390
50. A new twist on an old pathway - accessory Sec [corrected] systems. NW Rigel M Braunstein, Mol Microbiol 2008 69 291 302 10.1111/j.1365-2958.2008. 06294.x 18544071 (Pubitemid 351988016)
51. Towards the proteome of Mycobacterium tuberculosis. I Rosenkrands A King K Weldingh M Moniatte E Moertz P Andersen, Electrophoresis 2000 21 3740 3756 10.1002/1522-2683(200011)21:17<3740::AID-ELPS3740>3.0.CO;2-3 11271494
52. Mapping and identification of Mycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection. I Rosenkrands K Weldingh S Jacobsen CV Hansen W Florio I Gianetri P Andersen, Electrophoresis 2000 21 935 948 10.1002/(SICI)1522-2683(20000301)21:5<935:: AID-ELPS935>3.0.CO;2-P 10768780 (Pubitemid 30194073)
53. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. J Mattow UE Schaible F Schmidt K Hagens F Siejak G Brestrich G Haeselbarth EC Muller PR Jungblut SH Kaufmann, Electrophoresis 2003 24 3405 3420 10.1002/elps.200305601 14595687 (Pubitemid 38089144)
54. Membrane and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. H Målen FS Berven T Softeland MO Arntzen CS D'Santos GA De Souza HG Wiker, Proteomics 2008 8 1859 1870 10.1002/pmic. 200700528 18442171 (Pubitemid 351678287)
55. Cell wall proteome analysis of Mycobacterium smegmatis strain MC2 155. Z He J De Buck, BMC Microbiol 10 121
56. High extracellular levels of Mycobacterium tuberculosis glutamine synthetase and superoxide dismutase in actively growing cultures are due to high expression and extracellular stability rather than to a protein-specific export mechanism. MV Tullius G Harth MA Horwitz, Infect Immun 2001 69 6348 6363 10.1128/IAI.69.10.6348-6363.2001 11553579 (Pubitemid 32885200)
57. The secretome of a recombinant BCG substrain reveals differences in hypothetical proteins. M Rodriguez-Alvarez ID Palomec-Nava G Mendoza-Hernandez Y Lopez-Vidal, Vaccine 28 3997 4001
58. Enhanced patient serum immunoreactivity to recombinant Mycobacterium tuberculosis CFP32 produced in the yeast Pichia pastoris compared to Escherichia coli and its potential for serodiagnosis of tuberculosis. C Benabdesselem DM Fathallah RC Huard H Zhu MA Jarboui K Dellagi JL Ho RM Barbouche, J Clin Microbiol 2006 44 3086 3093 10.1128/JCM.02672-05 16954231 (Pubitemid 44413735)
59. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. V Roupie M Romano L Zhang H Korf MY Lin KL Franken TH Ottenhoff MR Klein K Huygen, Infect Immun 2007 75 941 949 10.1128/IAI.01137-06 17145953 (Pubitemid 46203459)
60. High resolution electroelution of polyacrylamide gels for the purification of single proteins from Mycobacterium tuberculosis culture filtrate. K Weldingh A Hansen S Jacobsen P Andersen, Scand J Immunol 2000 51 79 86 10.1046/j.1365-3083.2000.00655.x 10632980 (Pubitemid 30074307)
61. Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. RN Coler DC Dillon YA Skeiky M Kahn IM Orme Y Lobet SG Reed MR Alderson, Vaccine 2009 27 223 233 10.1016/j.vaccine. 2008.10.056 19000730
62. Chemokine receptor-mediated delivery of mycobacterial MPT51 protein efficiently induces antigen-specific T-cell responses. M Uchijima T Nagata Y Koide, Vaccine 2008 26 5165 5169 10.1016/j.vaccine.2008.03.059 18456373
63. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. JT Belisle VD Vissa T Sievert K Takayama PJ Brennan GS Besra, Science 1997 276 1420 1422 10.1126/science.276.5317.1420 9162010 (Pubitemid 27235411)
64. Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64(190-198)-mtb8.4 in C57/BL6 mice. YQ Qie JL Wang BD Zhu Y Xu QZ Wang JZ Chen HH Wang, Scand J Immunol 2008 67 133 139 10.1111/j.1365-3083.2007.02048. x 18201368
65. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Y Luo B Wang L Hu H Yu Z Da W Jiang N Song Y Qie H Wang Z Tang Q Xian Y Zhang B Zhu, Vaccine 2009 27 6179 6185 10.1016/j.vaccine.2009.08. 018 19712772
66. Identification of a novel cytotoxic T lymphocyte epitope from CFP21, a secreted protein of Mycobacterium tuberculosis. H Lv Y Gao Y Wu M Zhai L Li Y Zhu W Liu Z Wu F Chen Y Qi, Immunol Lett
67. Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. D Charlet S Mostowy D Alexander L Sit HG Wiker MA Behr, Mol Microbiol 2005 56 1302 1313 10.1111/j.1365-2958.2005.04618.x 15882422 (Pubitemid 40756012)
68. Novel monoclonal antibodies against major antigens of Mycobacterium bovis. KP Lyashchenko HG Wiker M Harboe J McNair SV Komissarenko JM Pollock, Scand J Immunol 2001 53 498 502 10.1046/j.1365-3083.2001.00914.x 11309158 (Pubitemid 32382274)
69. Liberation of soluble proteins from live and dead mycobacterial cells and the implications for pathogenicity of tubercle bacilli hypothesis. HG Wiker, Scand J Immunol 2001 54 82 86 10.1046/j.1365-3083.2001.00946.x 11439152 (Pubitemid 32592332)
70. Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis. C Manca K Lyashchenko HG Wiker D Usai R Colangeli ML Gennaro, Infect Immun 1997 65 16 23 8975887 (Pubitemid 27008898)
71. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. S Nagai HG Wiker M Harboe M Kinomoto, Infect Immun 1991 59 372 382 1898899
72. Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. H Målen FS Berven KE Fladmark HG Wiker, Proteomics 2007 7 1702 1718 10.1002/pmic.200600853 17443846 (Pubitemid 46841830)
73. Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria. F Romain A Laqueyrerie P Militzer P Pescher P Chavarot M Lagranderie G Auregan M Gheorghiu G Marchal, Infect Immun 1993 61 742 750 8423100 (Pubitemid 23030868)
74. Functional genomics reveals extended roles of the Mycobacterium tuberculosis stress response factor sigmaH. S Mehra D Kaushal, J Bacteriol 2009 191 3965 3980 10.1128/JB.00064-09 19376862
75. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. JC Ferraz E Stavropoulos M Yang S Coade C Espitia DB Lowrie MJ Colston RE Tascon, Infect Immun 2004 72 6945 6950 10.1128/IAI.72.12.6945-6950.2004 15557616 (Pubitemid 39552362)
76. Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis. PR Souza CR Zarate-Blades JI Hori SG Ramos DS Lima T Schneider RS Rosada LG Torre MH Santana IT Brandao AP Masson AA Coelho-Castelo VL Bonato FC Galetti ED Gonçalves DA Botte JB Machado CL Silva, Expert Opin Biol Ther 2008 8 1255 1264 10.1517/14712598.8.9. 1255 18694348
77. Mycobacterium tuberculosis Cpn60.2 and DnaK are located on the bacterial surface, where Cpn60.2 facilitates efficient bacterial association with macrophages. TB Hickey LM Thorson DP Speert M Daffe RW Stokes, Infect Immun 2009 77 3389 3401 10.1128/IAI.00143-09 19470749
78. Multiple moonlighting functions of mycobacterial molecular chaperones. B Henderson PA Lund AR Coates, Tuberculosis (Edinb) 90 119 124
79. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. GR Stewart VA Snewin G Walzl T Hussell P Tormay P O'Gaora M Goyal J Betts IN Brown DB Young, Nat Med 2001 7 732 737 10.1038/89113 11385512 (Pubitemid 32588031)
80. WHO REPORT Global Tuberculosis control Brazil. WHO, World Health Organization 2009
81. WHO vaccine-preventable diseases:monitoring system - 2009 global summary. Immunization W-EPo, 2009 Section 3 243 380
82. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. D Hayashi T Takii N Fujiwara Y Fujita I Yano S Yamamoto M Kondo E Yasuda E Inagaki K Kanai A Fujiwara A Kawarazaki T Chiba K Onozaki, FEMS Immunol Med Microbiol 2009 56 116 128 10.1111/j.1574-695X.2009.00559.x 19453755
83. Tuberculin sensitivity in guinea-pigs after vaccination with varying doses of BCG of 12 different strains. A Ladefoged K Bunch-Christensen J Guld, Bull World Health Organ 1976 53 435 443 1086736
84. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. UK Laemmli, Nature 1970 227 680 685 10.1038/227680a0 5432063
85. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. V Neuhoff N Arold D Taube W Ehrhardt, Electrophoresis 1988 9 255 262 10.1002/elps.1150090603 2466658
86. In-gel digestion for mass spectrometric characterization of proteins and proteomes. A Shevchenko H Tomas J Havlis JV Olsen M Mann, Nat Protoc 2006 1 2856 2860 17406544